β2 adrenergic agonist attenuates house dust mite-induced allergic airway inflammation through dendritic cells

BMC Immunology

Shinichiro Hayashi²  Shinya Kimura²  Hideharu Shirai¹  Keigo Kurata¹  Hiroki Tashiro²  Koichiro Takahashi²  Go Kato² 

[1] Institute of Tokyo Environmental Allergy, 1-2-5, Yushima, Bunkyo-ku, Tokyo 113-0034, Japan;Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga 849-8501, Japan

关键词: Dendritic cells;    House dust mite;    β2 adrenergic agonist;    Bronchial asthma;   

Others  :  1077684
DOI  :  10.1186/s12865-014-0039-y

 received in 2014-04-29, accepted in 2014-09-15,  发布年份 2014

【 摘 要 】

Background

Long-acting β2 adrenergic agonists (LABAs) are commonly used combined with inhaled corticosteroids (ICS) to treat asthmatic patients. Previous reports suggest that LABAs have an anti-inflammatory effect in bronchial asthma, and this should be further investigated. The aim of this study was to investigate whether LABAs inhibit allergic airway inflammation and how this occurs.

Results

We assessed the effect of the LABA formoterol (FORM) on inflammatory cell responses in airway, lung and regional lymph nodes, using an HDM-induced murine allergic asthma model in vivo. The effect of FORM on cytokine production from bone marrow derived dendritic cells (BMDCs) stimulated with HDM was evaluated in vitro. Adoptive transfer of BMDCs pulsed with HDM in the presence or absence of FORM to naïve mice was performed and the inflammatory response to subsequent HDM challenge was analyzed. FORM treatment suppressed HDM-induced changes and caused an increase in the number of eosinophils and neutrophils in bronchoalveolar lavage. The concentration of IL-4 and IL-17 in lung tissue homogenate was elevated and led to an accumulation of IL-4, IL-13, IL-5 and IL-17 producing cells in regional lymph nodes. FORM inhibited the production of IL-6 and IL-23 from BMDCs stimulated with HDM in vitro, and enhanced IL-10 production. The BMDCs adoptive transfer experiment indicated that dendritic cells mediate the effect of FORM, since FORM treatment of BMDCs in vitro attenuated airway inflammation.

Conclusion

These results suggested that FORM modulates dendritic cell function and attenuates Th2 and Th17 responses induced by HDM. Thus, we propose that the clinical significance of LABAs should be re-investigated taking into account these immune-modulating effects.

【 授权许可】

   
2014 Kato et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Thomas WR, Hales BJ, Smith WA: House dust mite allergens in asthma and allergy. Trends Mol Med 2010, 16:321-328.
• [2]Morgan WJ, Crain EF, Gruchalla RS, O'Connor GT, Kattan M, Evans R 3rd, Stout J, Malindzak G, Smartt E, Plaut M, Walter M, Vaughn B, Mitchell H: Results of a home-based environmental intervention among urban children with asthma. N Engl J Med 2004, 351:1068-1080.
• [3]Gaffin JM, Phipatanakul W: The role of indoor allergens in the development of asthma. Curr Opin Allergy Clin Immunol 2009, 9:128-135.
• [4]Galli SJ, Tsai M, Piliponsky AM: The development of allergic inflammation. Nature 2008, 454:445-454.
• [5]Tattersfield AE, Knox AJ, Britton JR, Hall IP: Asthma. Lancet 2002, 360:1313-1322.
• [6]Al-Muhsen S, Johnson JR, Hamid Q: Remodeling in asthma. J Allergy Clin Immunol 2011, 128:451-462.
• [7]Minnicozzi M, Sawyer RT, Fenton MJ: Innate immunity in allergic disease. Immunol Rev 2011, 242:106-127.
• [8]Busse WW, Lemanske RF: Asthma. N Engl J Med 2001, 344:350-362.
• [9]Al-Ramli W, Prefontaine D, Chouiali F, Martin JG, Olivenstein R, Lemiere C, Hamid Q: T(H)17-associated cytokines (IL-17A and IL-17 F) in severe asthma. J Allergy Clin Immunol 2009, 123:1185-1187.
• [10]Linden A: Role of interleukin-17 and the neutrophil in asthma. Int Arch Allergy Immunol 2001, 126:179-184.
• [11]Banchereau J, Steinman RM: Dendritic cells and the control of immunity. Nature 1998, 392:245-252.
• [12]Dong C: TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat Rev Immunol 2008, 8:337-348.
• [13]Murphy KM, Ouyang W, Farrar JD, Yang J, Ranganath S, Asnagli H, Afkarian M, Murphy TL: Signaling and transcription in T helper development. Annu Rev Immunol 2000, 18:451-494.
• [14]Lambrecht BN, Hammad H: The role of dendritic and epithelial cells as master regulators of allergic airway inflammation. Lancet 2010, 376:835-843.
• [15]Miyamoto M, Tomaki M, Lotvall J, Linden A: Beta-adrenoceptor stimulation and neutrophil accumulation in mouse airways. Eur Respir J 2004, 24:231-237.
• [16]Masoli M, Weatherall M, Holt S, Beasley R: Moderate dose inhaled corticosteroids plus salmeterol versus higher doses of inhaled corticosteroids in symptomatic asthma. Thorax 2005, 60:730-734.
• [17]Barnes PJ: Scientific rationale for using a single inhaler for asthma control. Eur Respir J 2007, 29:587-595.
• [18]O'Connor BJ, Fuller RW, Barnes PJ: Nonbronchodilator effects of inhaled beta 2 agonists. Greater protection against adenosine monophosphate- than methacholine-induced bronchoconstriction in asthma. Am J Respir Crit Care Med 1994, 150:381-387.
• [19]Nance DM, Sanders VM: Autonomic innervation and regulation of the immune system (1987–2007). Brain Behav Immun 2007, 21:736-745.
• [20]Seiffert K, Hosoi J, Torii H, Ozawa H, Ding W, Campton K, Wagner JA, Granstein RD: Catecholamines inhibit the antigen-presenting capability of epidermal Langerhans cells. J Immunol 2002, 168:6128-6135.
• [21]Yanagawa Y, Matsumoto M, Togashi H: Adrenoceptor-mediated enhancement of interleukin-33 production by dendritic cells. Brain Behav Immun 2011, 25:1427-1433.
• [22]Takahashi K, Koga K, Linge HM, Zhang Y, Lin X, Metz CN, Al-Abed Y, Ojamaa K, Miller EJ: Macrophage CD74 contributes to MIF-induced pulmonary inflammation. Respir Res 2009, 10:33. BioMed Central Full Text
• [23]Fukuno Y, Hayashi S, Kohsa K, Fujisawa N, Tominaga M, Miller EJ, Nagasawa K: Chemokine receptor inhibitor, Antileukinate, suppressed ovalbumin-induced eosinophilic inflammation in the airway. Cytokine 2003, 22:116-125.
• [24]Takahashi K, Shibata T, Akashi-Takamura S, Kiyokawa T, Wakabayashi Y, Tanimura N, Kobayashi T, Matsumoto F, Fukui R, Kouro T, Nagai Y, Takatsu K, Saitoh S, Miyake K: A protein associated with Toll-like receptor (TLR) 4 (PRAT4A) is required for TLR-dependent immune responses. J Exp Med 2007, 204:2963-2976.
• [25]Cosmi L, Liotta F, Maggi E, Romagnani S, Annunziato F: Th17 cells: new players in asthma pathogenesis. Allergy 2011, 66:989-998.
• [26]Holgate ST: Innate and adaptive immune responses in asthma. Nat Med 2012, 18:673-683.
• [27]Herve J, Dubreil L, Tardif V, Terme M, Pogu S, Anegon I, Rozec B, Gauthier C, Bach JM, Blancou P: beta2-Adrenoreceptor agonist inhibits antigen cross-presentation by dendritic cells. J Immunol 2013, 190:3163-3171.
• [28]Nakagome K, Imamura M, Okada H, Kawahata K, Inoue T, Hashimoto K, Harada H, Higashi T, Takagi R, Nakano K, Hagiwara K, Kanazawa M, Dohi M, Nagata M, Matsushita S: Dopamine D1-like receptor antagonist attenuates Th17-mediated immune response and ovalbumin antigen-induced neutrophilic airway inflammation. J Immunol 2011, 186:5975-5982.
• [29]Teschemacher A, Lemoine H: Kinetic analysis of drug-receptor interactions of long-acting beta2 sympathomimetics in isolated receptor membranes: evidence against prolonged effects of salmeterol and formoterol on receptor-coupled adenylyl cyclase. J Pharmacol Exp Ther 1999, 288:1084-1092.
• [30]Akdis CA, Akdis M: Mechanisms and treatment of allergic disease in the big picture of regulatory T cells. J Allergy Clin Immunol 2009, 123:735-746.
• [31]Grainge CL, Lau LC, Ward JA, Dulay V, Lahiff G, Wilson S, Holgate S, Davies DE, Howarth PH: Effect of bronchoconstriction on airway remodeling in asthma. N Engl J Med 2011, 364:2006-2015.
• [32]Moore WC, Meyers DA, Wenzel SE, Teague WG, Li H, Li X, D'Agostino R Jr, Castro M, Curran-Everett D, Fitzpatrick AM, Gaston B, Jarjour NN, Sorkness R, Calhoun WJ, Chung KF, Comhair SA, Dweik RA, Israel E, Peters SP, Busse WW, Erzurum SC, Bleecker ER: Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 2010, 181:315-323.
• [33]Li X, Howard TD, Zheng SL, Haselkorn T, Peters SP, Meyers DA, Bleecker ER: Genome-wide association study of asthma identifies RAD50-IL13 and HLA-DR/DQ regions. J Allergy Clin Immunol 2010, 125:328-335.
• [34]Brasier AR, Victor S, Boetticher G, Ju H, Lee C, Bleecker ER, Castro M, Busse WW, Calhoun WJ: Molecular phenotyping of severe asthma using pattern recognition of bronchoalveolar lavage-derived cytokines. J Allergy Clin Immunol 2008, 121:30-37.
• [35]Humbert M, Berger W, Rapatz G, Turk F: Add-on omalizumab improves day-to-day symptoms in inadequately controlled severe persistent allergic asthma. Allergy 2008, 63:592-596.
• [36]Takayama G, Arima K, Kanaji T, Toda S, Tanaka H, Shoji S, McKenzie AN, Nagai H, Hotokebuchi T, Izuhara K: Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals. J Allergy Clin Immunol 2006, 118:98-104.
• [37]Nair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E, Hargreave FE, O'Byrne PM: Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009, 360:985-993.
• [38]Kurowska-Stolarska M, Kewin P, Murphy G, Russo RC, Stolarski B, Garcia CC, Komai-Koma M, Pitman N, Li Y, Niedbala W, McKenzie AN, Teixeira MM, Liew FY, Xu D: IL-33 induces antigen-specific IL-5+ T cells and promotes allergic-induced airway inflammation independent of IL-4. J Immunol 2008, 181:4780-4790.
• [39]Prefontaine D, Nadigel J, Chouiali F, Audusseau S, Semlali A, Chakir J, Martin JG, Hamid Q: Increased IL-33 expression by epithelial cells in bronchial asthma. J Allergy Clin Immunol 2010, 125:752-754.
• [40]Agache I, Ciobanu C, Agache C, Anghel M: Increased serum IL-17 is an independent risk factor for severe asthma. Respir Med 2010, 104:1131-1137.
• [41]Bullens DM, Truyen E, Coteur L, Dilissen E, Hellings PW, Dupont LJ, Ceuppens JL: IL-17 mRNA in sputum of asthmatic patients: linking T cell driven inflammation and granulocytic influx? Respir Res 2006, 7:135. BioMed Central Full Text
• [42]Egerton M, Shortman K, Scollay R: The kinetics of immature murine thymocyte development in vivo. Int Immunol 1990, 2:501-507.
• [43]Wenzel S: Severe asthma: from characteristics to phenotypes to endotypes. Clin Exp Allergy 2012, 42:650-658.
• [44]Lai X, Li J, Xiao X, Liu E, Zhang C, Wang H, Gjesing B, Zhong N, Spangfort MD: Specific IgG4 production during house dust mite immunotherapy among age, gender and allergic disease populations. Int Arch Allergy Immunol 2013, 160:37-46.
• [45]Nakano K, Higashi T, Hashimoto K, Takagi R, Tanaka Y, Matsushita S: Antagonizing dopamine D1-like receptor inhibits Th17 cell differentiation: preventive and therapeutic effects on experimental autoimmune encephalomyelitis. Biochem Biophys Res Commun 2008, 373:286-291.
• [46]Okada H, Inoue T, Hashimoto K, Suzuki H, Matsushita S: D1-like receptor antagonist inhibits IL-17 expression and attenuates crescent formation in nephrotoxic serum nephritis. Am J Nephrol 2009, 30:274-279.
• [47]Nakano K, Yamaoka K, Hanami K, Saito K, Sasaguri Y, Yanagihara N, Tanaka S, Katsuki I, Matsushita S, Tanaka Y: Dopamine induces IL-6-dependent IL-17 production via D1-like receptor on CD4 naive T cells and D1-like receptor antagonist SCH-23390 inhibits cartilage destruction in a human rheumatoid arthritis/SCID mouse chimera model. J Immunol 2011, 186:3745-3752.
• [48]Jaeschke R, O'Byrne PM, Mejza F, Nair P, Lesniak W, Brozek J, Thabane L, Cheng J, Schunemann HJ, Sears MR, Guyatt G: The safety of long-acting beta-agonists among patients with asthma using inhaled corticosteroids: systematic review and metaanalysis. Am J Respir Crit Care Med 2008, 178:1009-1016.
• [49]Sears MR, Ottosson A, Radner F, Suissa S: Long-acting beta-agonists: a review of formoterol safety data from asthma clinical trials. Eur Respir J 2009, 33:21-32.
• [50]de Vries F, Setakis E, Zhang B, van Staa TP: Long-acting β2-agonists in adult asthma and the pattern of risk of death and severe asthma outcomes: a study using the GPRD. Eur Respir J 2010, 36:494-502.
• [51]Wijesinghe M, Weatherall M, Perrin K, Harwood M, Beasley R: Risk of mortality associated with formoterol: a systematic review and meta-analysis. Eur Respir J 2009, 34:803-811.
• [52][http:/ / www.fda.gov/ Safety/ MedWatch/ SafetyInformation/ SafetyAlertsforHumanMedicalProducts / ucm201003.htm] webcite FDA Drug Safety Communication: New safety requirements for long-acting inhaled asthma medications called Long-Acting Beta-Agonists (LABAs). In Drug Safety and Availability, Postmarket Drug Safety Information for Patients and Providers. Rockville, MD: US Food and Drug Administration; Available at . Accessed on October 30, 2014.